Sherif Farag

  • 4164 Citations
  • 32 h-Index
1977 …2020

Research output per year

If you made any changes in Pure these will be visible here soon.

Publications

Article

Phase II trial of temsirolimus in patients with relapsed or refractory multiple myeloma

Farag, S. S., Zhang, S., Jansak, B. S., Wang, X., Kraut, E., Chan, K., Dancey, J. E. & Grever, M. R., Nov 2009, In : Leukemia Research. 33, 11, p. 1475-1480 6 p.

Research output: Contribution to journalArticle

65 Scopus citations

Phase I trial and pharmacokinetic study of high-dose clofarabine and busulfan and allogeneic stem cell transplantation in adults with high-risk and refractory acute leukemia

Farag, S. S., Wood, L. L., Schwartz, J. E., Srivastava, S., Nelson, R. P., Robertson, M. J., Abonour, R., Secrest, A., Cox, E., Baute, J., Sullivan, C., Kane, K. & Jones, D. R., Apr 2011, In : Leukemia. 25, 4, p. 599-605 7 p.

Research output: Contribution to journalArticle

Open Access
28 Scopus citations

Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: Evidence for lenalidomide-CCI-779 interaction via P-glycoprotein

Hofmeister, C. C., Yang, X., Pichiorri, F., Chen, P., Rozewski, D. M., Johnson, A. J., Lee, S., Liu, Z., Garr, C. L., Hade, E. M., Ji, J., Schaaf, L. J., Benson, D. M., Kraut, E. H., Hicks, W. J., Chan, K. K., Chen, C. S., Farag, S. S., Grever, M. R., Byrd, J. C. & 1 others, Phelps, M. A., Sep 1 2011, In : Journal of Clinical Oncology. 29, 25, p. 3427-3434 8 p.

Research output: Contribution to journalArticle

67 Scopus citations

Postremission therapy with low-dose interleukin 2 with or without intermediate pulse dose interleukin 2 therapy is well tolerated in elderly patients with acute myeloid leukemia: Cancer and Leukemia Group B study 9420

Farag, S. S., George, S. L., Lee, E. J., Baer, M., Dodge, R. K., Becknell, B., Fehniger, T., Silverman, L. R., Crawford, J., Bloomfield, C. D., Larson, R. A., Schiffer, C. A. & Caligiuri, M. A., Sep 2002, In : Clinical Cancer Research. 8, 9, p. 2812-2819 8 p.

Research output: Contribution to journalArticle

38 Scopus citations

Preclinical activity of a novel multiple tyrosine kinase and aurora kinase inhibitor, ENMD-2076, against multiple myeloma

Wang, X., Sinn, A. L., Pollok, K., Sandusky, G., Zhang, S., Chen, L., Liang, J., Crean, C. D., Suvannasankha, A., Abonour, R., Sidor, C., Bray, M. R. & Farag, S. S., Aug 2010, In : British journal of haematology. 150, 3, p. 313-325 13 p.

Research output: Contribution to journalArticle

31 Scopus citations

Preliminary efficacy of a brief family intervention to prevent declining quality of life secondary to parental bone marrow transplantation

Fife, B. L., Von Ah, D. M., Spath, M. L., Weaver, M. T., Yang, Z., Stump, T. & Farag, S., Feb 1 2017, In : Bone marrow transplantation. 52, 2, p. 285-291 7 p.

Research output: Contribution to journalArticle

4 Scopus citations

Pretransplant HLA typing revealed loss of heterozygosity in the major histocompatibility complex in a patient with acute myeloid leukemia

Lobashevsky, A. L., Krueger-Sersen, M., Britton, R. M., Littrell, C. A., Singh, S., Cui, C. P., Kashi, Z., Martin, R. K., Breman, A. M., Vance, G. H. & Farag, S. S., Apr 2019, In : Human Immunology. 80, 4, p. 257-262 6 p.

Research output: Contribution to journalArticle

Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: Results from Cancer and Leukemia Group B 8461

Farag, S. S., Archer, K. J., Mrózek, K., Ruppert, A. S., Carroll, A. J., Vardiman, J. W., Pettenati, M. J., Baer, M. R., Qumsiyeh, M. B., Koduru, P. R., Ning, Y., Mayer, R. J., Stone, R. M., Larson, R. A. & Bloomfield, C. D., Jul 1 2006, In : Blood. 108, 1, p. 63-73 11 p.

Research output: Contribution to journalArticle

242 Scopus citations

Prognostic significance of additional cytogenetic abnormalities in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha: a Cancer and Leukemia Group B study.

Farag, S. S., Ruppert, A. S., Mrózek, K., Carroll, A. J., Pettenati, M. J., Le Beau, M. M., Peterson, B. L., Powell, B. L., Ozer, H., Silver, R. T., Larson, R. A. & Bloomfield, C. D., Jul 2004, In : International journal of oncology. 25, 1, p. 143-151 9 p.

Research output: Contribution to journalArticle

19 Scopus citations

Prophylaxis with Sirolimus and Tacrolimus ± Antithymocyte Globulin Reduces the Risk of Acute Graft-versus-Host Disease without an Overall Survival Benefit Following Allogeneic Stem Cell Transplantation

Rosenbeck, L. L., Kiel, P. J., Kalsekar, I., Vargo, C., Baute, J., Sullivan, C. K., Wood, L., Abdelqader, S., Schwartz, J., Srivastava, S., Abonour, R., Robertson, M. J., Nelson, R. P., Cornetta, K., Fausel, C. A. & Farag, S. S., Jun 1 2011, In : Biology of Blood and Marrow Transplantation. 17, 6, p. 916-922 7 p.

Research output: Contribution to journalArticle

24 Scopus citations

Quantification of non-specific binding of magnetic micro- and nanoparticles using cell tracking velocimetry: Implication for magnetic cell separation and detection

Chalmers, J. J., Xiong, Y., Jin, X., Shao, M., Tong, X., Farag, S. & Zborowski, M., Apr 15 2010, In : Biotechnology and Bioengineering. 105, 6, p. 1078-1093 16 p.

Research output: Contribution to journalArticle

28 Scopus citations

Reduced-intensity allogeneic transplantation provides high event-free and overall survival in patients with advanced indolent B cell malignancies: CALGB 109901

Shea, T., Johnson, J., Westervelt, P., Farag, S., McCarty, J., Bashey, A., Isola, L., Baxter-Lowe, L. A., Kelly, M., Owzar, K. & Linker, C., Sep 1 2011, In : Biology of Blood and Marrow Transplantation. 17, 9, p. 1395-1403 9 p.

Research output: Contribution to journalArticle

51 Scopus citations

Reduced intensity conditioned allograft yields favorable survival for older adults with B-cell acute lymphoblastic leukemia

Rosko, A. E., Wang, H. L., de Lima, M., Sandmaier, B., Khoury, H. J., Artz, A., Brammer, J., Bredeson, C., Farag, S., Kharfan-Dabaja, M., Lazarus, H. M., Marks, D. I., Martino Bufarull, R., McGuirk, J., Mohty, M., Nishihori, T., Nivison-Smith, I., Rashidi, A., Ringden, O., Seftel, M. & 3 others, Weisdorf, D., Bachanova, V. & Saber, W., Jan 1 2017, In : American Journal of Hematology. 92, 1, p. 42-49 8 p.

Research output: Contribution to journalArticle

24 Scopus citations

Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation for Patients with Hematologic Malignancies Who Relapse following Autologous Transplantation: A Multi-institutional Prospective Study from the Cancer and Leukemia Group B (CALGB trial 100002)

Bashey, A., Owzar, K., Johnson, J. L., Edwards, P. S., Kelly, M., Baxter-Lowe, L. A., Devine, S., Farag, S., Hurd, D., Ball, E., McCarthy, P., Lister, J., Shea, T. C. & Linker, C., Apr 1 2011, In : Biology of Blood and Marrow Transplantation. 17, 4, p. 558-565 8 p.

Research output: Contribution to journalArticle

7 Scopus citations

Standard pentostatin dose reductions in renal insufficiency are not adequate: Selected patients with steroid-refractory acute graft-versus-host disease

Poi, M. J., Hofmeister, C. C., Johnston, J. S., Edwards, R. B., Jansak, B. S., Lucas, D. M., Farag, S. S., Dalton, J. T., Devine, S. M., Grever, M. R. & Phelps, M. A., Aug 1 2013, In : Clinical Pharmacokinetics. 52, 8, p. 705-712 8 p.

Research output: Contribution to journalArticle

4 Scopus citations

T Cell-Depleted Partial Matched Unrelated Donor Transplant for Advanced Myeloid Malignancy: KIR Ligand Mismatch and Outcome

Weisdorf, D., Cooley, S., Devine, S., Fehniger, T. A., DiPersio, J., Anasetti, C., Waller, E. K., Porter, D., Farag, S., Drobyski, W., Defor, T., Haagenson, M., Curtsinger, J. & Miller, J., Jun 1 2012, In : Biology of Blood and Marrow Transplantation. 18, 6, p. 937-943 7 p.

Research output: Contribution to journalArticle

20 Scopus citations

The Effect of KIR Ligand Incompatibility on the Outcome of Unrelated Donor Transplantation: A Report from the Center for International Blood and Marrow Transplant Research, the European Blood and Marrow Transplant Registry, and the Dutch Registry

Farag, S. S., Bacigalupo, A., Eapen, M., Hurley, C., Dupont, B., Caligiuri, M. A., Boudreau, C., Nelson, G., Oudshoorn, M., van Rood, J., Velardi, A., Maiers, M., Setterholm, M., Confer, D., Posch, P. E., Anasetti, C., Kamani, N., Miller, J. S., Weisdorf, D. & Davies, S. M., Aug 2006, In : Biology of Blood and Marrow Transplantation. 12, 8, p. 876-884 9 p.

Research output: Contribution to journalArticle

187 Scopus citations

The novel histone deacetylase inhibitor, AR-42, inhibits gp130/Stat3 pathway and induces apoptosis and cell cycle arrest in multiple myeloma cells

Zhang, S., Suvannasankha, A., Crean, C. D., White, V. L., Chen, C. S. & Farag, S. S., Jul 1 2011, In : International Journal of Cancer. 129, 1, p. 204-213 10 p.

Research output: Contribution to journalArticle

32 Scopus citations

The potential role of PD0332991 (Palbociclib) in the treatment of multiple myeloma

Altenburg, J. D. & Farag, S. S., Feb 1 2015, In : Expert Opinion on Investigational Drugs. 24, 2, p. 261-271 11 p.

Research output: Contribution to journalArticle

10 Scopus citations

Therapeutic applications of immunomagnetic cell selection: A review

Farag, S. S., May 1 2002, In : European Cells and Materials. 3, SUPPL. 2, p. 37-40 4 p.

Research output: Contribution to journalArticle

3 Scopus citations

Therapy-related myelodysplasia and leukemia occur infrequently following VP-16 priming and autotransplantation without total body irradiation

Copelan, E., Hoshaw-Woodard, S., Elder, P., Penza, S., Farag, S., Marcucci, G., Lin, T., Ezzone, S., Scholl, M. D., Bechtel, T., Lemeshow, S. & Avalos, B., Jul 1 2004, In : Bone Marrow Transplantation. 34, 1, p. 85-87 3 p.

Research output: Contribution to journalArticle

9 Scopus citations
Chapter

Cord Blood Hematopoietic Cell Transplantation

Broxmeyer, H. E., Farag, S. S. & Rocha, V., Jan 1 2016, Thomas' Hematopoietic Cell Transplantation: Fifth Edition. Wiley-Blackwell, Vol. 1-2. p. 437-455 19 p.

Research output: Chapter in Book/Report/Conference proceedingChapter

13 Scopus citations

Cytokine Modulation of the Innate Immune System in the Treatment of Leukemia and Lymphoma

Farag, S. S. & Caligiuri, M. A., Dec 1 2004, Treatment of Leukemia and Lymphoma. p. 295-318 24 p. (Advances in Pharmacology; vol. 51).

Research output: Chapter in Book/Report/Conference proceedingChapter

23 Scopus citations

Natural killer cell activity and killer immunoglobulin-like receptors in hematopoietic stem cell transplantation

Ruggeri, L., Zhang, S. & Farag, S. S., Oct 15 2009, Hematopoietic Stem Cell Transplantation. Bishop, M. (ed.). p. 47-69 23 p. (Cancer Treatment and Research; vol. 144).

Research output: Chapter in Book/Report/Conference proceedingChapter

2 Scopus citations
Comment/debate

Erratum: (Clinical Cancer Research (September 2002) (2812-2819))

Farag, S. S., Nov 1 2002, In : Clinical Cancer Research. 8, 11, 1 p.

Research output: Contribution to journalComment/debate

Killer Cell Immunoglobulin-Like Receptor Ligand Mismatching: To Match or Mismatch?

Farag, S. S., Feb 1 2016, In : Biology of Blood and Marrow Transplantation. 22, 2, p. 192-194 3 p.

Research output: Contribution to journalComment/debate

3 Scopus citations
Conference contribution

Generation of alloreactive T-cells in-vitro for cellular therapy

Shao, M., Farag, S. & Chalmers, J., 2005, AIChE Annual Meeting, Conference Proceedings. p. 8690 1 p.

Research output: Chapter in Book/Report/Conference proceedingConference contribution

The scale-up of T cell depletion for mismatched bone marrow transplants

Xiong, Y., Tong, X., Farag, S. & Chalmers, J., 2005, AIChE Annual Meeting, Conference Proceedings. p. 9145 1 p.

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Letter

Diffuse alveolar hemorrhage following gemtuzumab ozogamicin [2]

Lin, T. S., Penza, S. L., Avalos, B. R., Lucarelli, M. R., Farag, S. S., Byrd, J. C. & Copelan, E. A., Apr 2005, In : Bone marrow transplantation. 35, 8, p. 823-824 2 p.

Research output: Contribution to journalLetter

9 Scopus citations

Phase II study of topotecan and cyclophosphamide in patients with relapsed and refractory multiple myeloma

Kraut, E. H., Young, D., Farag, S., James, A. G. & Solove, R. J., Oct 1 2005, In : Leukemia Research. 29, 10, p. 1233-1234 2 p.

Research output: Contribution to journalLetter

3 Scopus citations
Review article

Biology and clinical impact of human natural killer cells

Farag, S. S., VanDeusen, J. B., Fehniger, T. A. & Caligiuri, M. A., Jul 2003, In : International Journal of Hematology. 78, 1, p. 7-17 11 p.

Research output: Contribution to journalReview article

78 Scopus citations

Chronic lymphocytic leukemia.

Kay, N. E., Hamblin, T. J., Jelinek, D. F., Dewald, G. W., Byrd, J. C., Farag, S., Lucas, M. & Lin, T., 2002, In : Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program. p. 193-213 21 p.

Research output: Contribution to journalReview article

74 Scopus citations

DC therapy? Let the natural killer answer

Farag, S. S., Sep 15 2005, In : Blood. 106, 6, 1 p.

Research output: Contribution to journalReview article

1 Scopus citations

Immunotherapeutic concepts to target acute myeloid leukemia: Focusing on the role of monoclonal antibodies, hypomethylating agents and the leukemic microenvironment

Gbolahan, O. B., Zeidan, A. M., Stahl, M., Zaid, M. A., Farag, S., Paczesny, S. & Konig, H., Aug 2017, In : International journal of molecular sciences. 18, 8, 1660.

Research output: Contribution to journalReview article

15 Scopus citations
1 Scopus citations

Natural killer cell receptors: New biology and insights into the graft-versus-leukemia effect

Farag, S. S., Fehniger, T. A., Ruggeri, L., Velardi, A. & Caligiuri, M. A., Sep 15 2002, In : Blood. 100, 6, p. 1935-1947 13 p.

Research output: Contribution to journalReview article

400 Scopus citations

New directions in natural killer cell-based immunotherapy of human cancer

Farag, S. S., Fehniger, T. A., Becknell, B., Blaser, B. W. & Caligiuri, M. A., Apr 1 2003, In : Expert Opinion on Biological Therapy. 3, 2, p. 237-250 14 p.

Research output: Contribution to journalReview article

31 Scopus citations

Radiation-free regimens result in similar outcomes of allogeneic hematopoietic progenitor cell transplation in patients aged ≥ 50 years compared to young adults with low-risk disease

Farag, S. S., Elder, P. J., Marcucci, G., Penza, S., Mrozek, E., Molina, A., Lin, T., Avalos, B. R. & Copelan, E., Jan 1 2003, In : Bone marrow transplantation. 31, 2, p. 87-93 7 p.

Research output: Contribution to journalReview article

12 Scopus citations

The potential role of Aurora kinase inhibitors in haematological malignancies

Farag, S. S., Dec 2011, In : British journal of haematology. 155, 5, p. 561-579 19 p.

Research output: Contribution to journalReview article

43 Scopus citations
16 Scopus citations

Vaccine and cell-based therapeutic approaches in acute myeloid leukemia

Agrawal, V., Gbolahan, O. B., Stahl, M., Zeidan, A. M., Abu Zaid, M., Farag, S. S. & Konig, H., 2020, In : Current cancer drug targets. 20, 7, p. 473-489 17 p.

Research output: Contribution to journalReview article

Short survey

Chronic graft-versus-host disease: Where do we go from here?

Farag, S. S., Mar 1 2004, In : Bone Marrow Transplantation. 33, 6, p. 569-577 9 p.

Research output: Contribution to journalShort survey

44 Scopus citations